Health Trials

Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing

ConditionCigarette Smoking
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorVirginia Polytechnic Institute and State University

About this trial

This study will investigate the effects of normal-nicotine versus low-nicotine cigarette availability in the context of four tax proposals (Tobacco Parity, Nicotine-Content, Harm-Reduction, and Modified Risk Tobacco Product-based taxes) on tobacco product purchasing patterns in a virtual marketplace.

Eligibility criteria

Qualifiers

provide informed consent

provide a breath carbon monoxide sample ≥ 8 ppm,

be at least 21 years of age (the legal age to purchase tobacco),

smoke at least 10 cigarettes daily, and

Disqualifiers

report uncontrolled physical or mental health conditions (e.g., uncontrolled diabetes, high blood pressure, major depressive disorder, etc.),

use of smoking cessation medications (e.g., nicotine replacement, bupropion, varenicline) in the past 30 days,

report concrete, immediate plans to alter/quit using their usual tobacco products in the next 30 days,

be pregnant or lactating, or

Trial design

Treatments tested in this trial

  • Harm Reduction Tax - Normal Nicotine Cigarettes Available
  • Harm Reduction Tax - Normal Nicotine Cigarettes Not Available
  • Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Available
  • Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Not Available
  • Nicotine Content Tax - Normal Nicotine Cigarettes Available
  • Nicotine Content Tax - Normal Nicotine Cigarettes Not Available
  • Tobacco Parity Tax - Normal Nicotine Cigarettes Available
  • Tobacco Parity Tax - Normal Nicotine Cigarettes Not Available

Treatment groups

316 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Virginia Polytechnic Institute and State University

Lead sponsor

Roswell Park Comprehensive Cancer Center

Collaborator

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov